InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Participants with Methamphetamine Use Disorder
IXT-m200 produced significant changes in primary endpoint of methamphetamine pharmacokinetics, with favorable data for secondary endpoints and safety LITTLE ROCK, AR, USA, April 19, 2021 - InterveXion Therapeutics, a private clinical-stage biopharmaceutical company...
read moreInterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Overdose
"Meth-OD" trial will be first known clinical trial specifically for patients suffering from methamphetamine overdose LITTLE ROCK, ARKANSAS, USA, October 5, 2020 /EINPresswire.com/ -- InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced...
read moreInterveXion Therapeutics Awarded Federal Grant to Fund Ongoing Development Program for IXT-m200 for Methamphetamine Use Disorder
Grant fully funds manufacture of clinical supplies for Phase 2b clinical study and supports initiation of development of new subcutaneous formulation of IXT-m200 Little Rock, AR (01 May 2020) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical...
read moreBinding Methamphetamine to Release People from Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of people with methamphetamine overdose and methamphetamine use disorder. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and has demonstrated positive Phase 2 clinical proof-of-concept data (STAMPOUT; NCT03336866). We are currently evaluating IXT-m200 in a Phase 2 study for methamphetamine overdose (Meth-OD), and we are planning another Phase 2 study of IXT-m200 in people with methamphetamine use disorder (OUTLAST).